MK-8617 NEW
| Price | $40 | $68 | $148 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-29 |
Product Details
| Product Name: MK-8617 | CAS No.: 1187990-87-9 |
| Purity: 100% | Supply Ability: 10g |
| Release date: 2025/04/29 |
Product Introduction
Bioactivity
| Name | MK-8617 |
| Description | MK-8617 is an orally available HIF PHD1 3 pan-inhibitor, inhibiting PHD1/2/3 (IC50: 1.0/1.0/14 nM). |
| In vitro | In vitro, MK-8617 hasn't markedly inhibitory for CYP1A2, 3A4, 2B6, 2C9, 2C19, or 2D6 (IC50>60 μM), and is a moderate reversible inhibitor of CYP2C8 (IC50: 1.6 μM). MK-8617 (10 μM) is inactive against a general panel of 171 radioligand binding and enzymatic assays. |
| In vivo | In liver microsomes (+NADPH) from rat, dog, and monkey, tritiated MK-8617 exhibits minimal metabolic turnover (<10%), but the significant turnover (34%) in HLMs after 60 min (10 μM compound, 1 mg/mL microsomal protein). MK-8617 has good oral bioavailability across species (36?71%), with low clearance and volume of distribution. Increases in circulating reticulocytes are observed at 5 and 15 mg/kg 3 days after challenge and at the 15 mg/kg 4 days after challenge. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 1 mg/mL (2.26 mM), Sonication is recommended. |
| Keywords | PHD3 | PHD2 | PHD1 | MK-8617 | MK 8617 | Inhibitor | inhibit | Hypoxia-inducible factors | HIFs | HIFProlylHydroxylase | HIF-PH | HIF/HIFProlylHydroxylase | HIF/HIF Prolyl-Hydroxylase | HIF/HIF ProlylHydroxylase | HIF Prolyl-Hydroxylase | HIF ProlylHydroxylase | HIF |
| Inhibitors Related | Deferoxamine Mesylate | Hydralazine hydrochloride | 1,4-DPCA | Chlorogenic Acid | Glucosamine | Hydroxycitric acid tripotassium hydrate | Glucosamine hydrochloride | Minocycline hydrochloride | Chloramphenicol | Oltipraz | Albendazole | Glucosamine sulfate |
| Related Compound Libraries | Reprogramming Compound Library | Glycolysis Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10g |
VIP1Y
|
Wuhan Kejiefeng Trading Co.,Ltd
|
2025-05-07 | |
| $5.00/1Box |
VIP1Y
|
Hebei Jiafan Trading Company Limited
|
2025-01-08 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $2.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY